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Background: As persons with HIV live longer, data regarding the epidemiology of colorectal cancer are required to
optimize the long-term management of these patients. The purpose of this systematic review and meta-analysis is
to synthesize evidence regarding the incidence of colorectal cancer in persons with HIV.
Methods/design: Our primary outcome is the standardized incidence ratio of colorectal cancer among persons with
HIV relative to rates in persons not living with HIV. Our secondary objectives are to summarize the evidence for
differences with respect to stage at diagnosis, site of disease, and mortality due to colorectal cancer. We will search
electronic bibliographic databases from their inception date, as well as conference proceedings and reference lists of
included articles. Two investigators will independently screen citations and full-text articles, conduct data abstraction,
and appraise study quality. We will examine clinical, methodological, and statistical heterogeneity among studies prior
to conducting meta-analysis. Random effects meta-analysis methods will be employed to estimate standardized
incidence ratios. These data will inform the development of guidelines for colorectal cancer screening in persons with
HIV.
Systematic review registration: PROSPERO CRD42014013449
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Rates of AIDS-defining cancers such as Kaposi’s sarcoma
and non-Hodgkin’s lymphoma have declined markedly
among persons with HIV infection in the years following
the introduction of combination antiretroviral therapy
(cART) [1,2]. However, the incidence of certain cancers
not traditionally associated with HIV has increased more
than threefold in this population over the same period,
such that these non-AIDS-defining cancers now account
for an increasing proportion of deaths among persons
with HIV [2-5]. Consequently, research regarding the in-
cidence, natural history, and outcomes of cancers not
historically associated with HIV infection is required to* Correspondence: tantoniou@smh.ca
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unless otherwise stated.inform patient care and develop age-appropriate screen-
ing guidelines in this population.
Colorectal cancer (CRC) is the third leading cause of
cancer-related death in North America, with an esti-
mated 9,200 Canadians dying from this disease in 2012
[6,7]. As individuals with HIV are living longer, it is ex-
pected that the number of cases of CRC among this
population will increase simply by virtue of the age-
related risk for this disease. Yet, in contrast to human
papillomavirus-associated rectal cancer, very little is
known about the epidemiology of CRC in persons with
HIV, and the available literature is inconsistent with re-
spect to the risk of this disease in persons with HIV.
Specifically, the standardized incidence ratio for CRC in
persons with HIV compared with the general population
has ranged from 0.45 to 2.3 in various studies [1,8-16].
Similarly, although small studies have found that CRC is
diagnosed at a younger age relative to non-HIV-infectedal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Nguemo et al. Systematic Reviews  (2015) 4:72 Page 2 of 5individuals, these findings were subsequently disputed
by a larger study that found similar standardized inci-
dence ratios for CRC when stratification by age was
undertaken [12]. In addition, the prevalence of aden-
omatous polyps in persons with HIV exceeds that of the
general population in most, but not all, studies [17-21].
Previously published meta-analyses of studies reported
up to March 2007 and March 2009 found standardized
incidence ratios and 95% confidence intervals of CRC in
persons with HIV of 0.97 (0.78 to 1.19) [22] and 1.1
(0.69 to 1.7) [23], respectively. However, new studies
have been published since the last review was under-
taken [3,5,24-27], and a systematic review of the clinical
features of CRC in persons with HIV relative to unin-
fected individuals has not been reported. Accordingly,
we plan to conduct a systematic review and meta-
analysis of publications reporting the risk of CRC in
persons with HIV, using estimates of the standardized
incidence ratio relative to rates in a referent population
of persons not living with HIV. Our secondary objectives
are to summarize the evidence for differences between
persons with and without HIV with respect to stage at
diagnosis, site of disease occurrence, and treatment out-
comes, focusing specifically on mortality due to CRC.
Such data are required to inform screening guidelines




We will conduct a systematic review and meta-analysis
of the epidemiology and clinical presentation of CRC in
persons with HIV.
Outcomes
Our primary outcome is the standardized incidence ratio
of CRC among persons with HIV relative to rates in per-
sons not infected with HIV. As secondary outcomes, we
will examine stage of diagnosis, the standardized mortal-
ity ratio as well, site of disease, and treatment outcomes
among persons with HIV relative to a referent HIV-
uninfected population.
Inclusion criteria
We will include any published peer-reviewed and gray
literature (e.g., conference abstracts, white papers) that
provide a comparison of the incidence of CRC in adults
with HIV and a referent population of persons who are
not living with HIV. Included studies will report informa-
tion sufficient to obtain standardized incidence ratios and
95% confidence intervals, including the total number of
adults with HIV observed, the duration of follow-up, the
observed number of CRCs occurring during follow-up in
adults with HIV (identified using disease registries), andcorresponding data for the HIV-uninfected comparator
population. Prospective and retrospective cohort studies
will be eligible for inclusion. We will include cross-
sectional, case–control, and cohort studies that provide
data regarding risk factors for CRC in persons with HIV,
stage at diagnosis, site of disease, treatment mode, and
CRC mortality. When two or more publications from one
institution or cohort are available, we will review each art-
icle to consider the extent of duplication in the reported
outcomes. For our main outcome, we will include results
from the most recent publication only. Publications with
overlapping populations will be retained if they provide in-
formation on outcomes that complements or differs from
the most recent report. We will make no restrictions ac-
cording to country or language of publication. We will ex-
clude animal studies, case reports, case series, and
randomized trials of CRC treatment, as well as studies
where CRC is identified by self-report or patient question-
naire. In addition, we will exclude studies comparing the
incidence, natural history, and treatment outcome of
human papillomavirus-associated anal and rectal cancers.
Search strategy
We will develop a search strategy in consultation with
an information scientist. We will search the following
electronic bibliographic databases from inception onwards:
Ovid MEDLINE, Ovid EMBASE, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), Scopus,
and Web of Science (see Additional file 1 for MEDLINE
search strategy). The search will include the terms HIV,
colorectal cancer, AIDS, and incidence. We will also search
abstracts for the last 5 years from the following HIV/AIDS
conferences: Conference on Retroviruses and Opportunistic
Infections, International AIDS Conference, and Inter-
national AIDS Society (IAS). Finally, we will scan the bibli-
ographies of all studies meeting the inclusion criteria for
additional relevant citations.
Study selection
We will import all citations obtained using the search
strategy into DistillerSR™ to facilitate study screening
and selection, de-duplicating citations prior to undertak-
ing the abstract review. Study selection will proceed ac-
cording to the three stages as described below:
Stage 1: Broad overview
During this stage, two reviewers will independently scan
all titles and abstracts of all citations for articles that ob-
viously do not merit further consideration. Specific
points that will be considered when reviewing the title
and abstract include whether the study includes adults
with HIV, examines the incidence of CRC relative to a
referent HIV-uninfected population, and/or provides the
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sons with HIV and a referent population.
Stage 2: Pilot testing of customized checklist for study
selection
A customized form reflecting the previously described
inclusion will be pilot tested by two reviewers. Specific-
ally, the data collection form will be developed and
stored on DistillerSR™ software and will be applied by
two reviewers independently to a sample of 50 abstracts
to ensure consistency of use and clarity of the instru-
ment. A Cohen’s kappa statistic [28] will be estimated to
measure inter-rater reliability, and screening will begin
when >60% agreement is achieved.
Stage 3: Assessment of remaining studies for inclusion
Abstracts of studies remaining following stage 1 will be
reviewed independently by two reviewers using the cus-
tomized checklist developed in stage 2. We will ascertain
the relevance of the studies without blinding to author
names, institutions, or journal of publication. Differences
in opinion will be resolved by consensus and discussion
with a third author in situations where consensus cannot
be reached. In cases where abstracts are not provided,
are unclear, or there is any other reason for uncertainty,
the full article will be obtained before making the deci-
sion regarding eligibility for inclusion. When abstracts
are not available in English, the assistance of translators
will be obtained. Full-text versions of the papers identi-
fied from the abstract screening process will be subse-
quently retrieved and assessed independently by two
reviewers for inclusion in the review.
Data abstraction
The same investigators involved in study selection will
independently extract data from eligible studies using a
pre-designed data extraction form. The data extraction
form will be pilot tested with a sample of five to ten
studies to ensure clarity and consistency. We will ab-
stract data regarding study methodology and sociodemo-




Year of publication, language of publication, country in w
Design Type of study, study temporality, population-based, type o
Study
participants
Age, sex, number of persons with HIV, number of control
acquisition risk factors, CD4+ cell count and viral load at t
therapy), description of control population (healthy individ
and reason(s) for loss to follow-up, comorbid illness
Outcome
measures
Standardized incidence ratio of colorectal cancer, number
screening/diagnostic modality (fecal occult blood test, col
related), standardized mortality ratio, treatment received, tof potential sources of heterogeneity with stratified ana-
lyses and/or meta-regression. We will also extract avail-
able data comparing the clinical characteristics of CRC
among persons with and without HIV, including age at
diagnosis, stage of disease (I, II, III, IV), disease grade
(well differentiated, moderately differentiated, poorly dif-
ferentiated, undifferentiated), site of disease (right, left,
rectosigmoid, synchronous), nature of treatment re-
ceived (surgery, radiofrequency ablation, cryosurgery,
chemotherapy, radiation, targeted therapy), and out-
comes (remission, local recurrence, regional recurrence,
distant recurrence, unknown site recurrence, and death).
Discrepancies arising during the data abstraction process
will be resolved by consensus or discussion with a third
party if agreement cannot be reached.
Study quality
The same reviewers involved in data abstraction will in-
dependently evaluate the quality of eligible studies using
the Newcastle-Ottawa Scale [29,30]. We decided a priori
that studies meeting seven or more of the nine Newcastle-
Ottawa Scale criteria were to be considered high quality.
We will also use a modified version of the framework de-
veloped by Hayden and colleagues [31,32] to evaluate study
participation, study attrition, and outcome measurement.
Assessment of heterogeneity
We will examine clinical, methodological, and statistical
heterogeneity among studies prior to conducting meta-
analysis. Clinical heterogeneity will be evaluated by
reviewing studies for differences in patient characteris-
tics that may influence the risk of CRC, such as age and
sex, as well as whether the study was conducted in the
pre- or post-cART era. We will assess studies for meth-
odological heterogeneity by examining differences in
HIV status ascertainment and outcomes assessment, par-
ticularly for the secondary outcomes. Another source of
methodological heterogeneity that will be considered is
whether standardized incidence ratios are crude or adjusted
estimates, methods (if any) of confounder adjustment, and
the confounders that have been adjusted for in each study.hich study conducted
f center where study was conducted, duration of study, follow-up time
subjects, description of persons with HIV (years diagnosed with HIV, HIV
ime of colorectal cancer diagnosis, percentage receiving antiretroviral
uals, general population, other underlying medical condition), attrition
s of observed and expected cases, stage of diagnosis, site of cancer,
onoscopy, sigmoidoscopy, other), number of deaths (total and cancer
reatment outcomes
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ability that is due to heterogeneity rather than chance using
the I2 statistic [33].Statistical analysis
We will use random effects meta-analysis to estimate a
pooled effect size of the standardized incidence ratio for
CRC. In the event of extensive heterogeneity (I2 > 60%), we
will conduct subgroup analyses or meta-regression if there
are more than ten studies providing data regarding the pri-
mary outcome. Specific variables we will examine in sub-
group analyses or meta-regression include age, study
quality, sex, era of rate estimation (pre- or post-cART era),
and mean CD4+ count. If applicable, we will also compare
studies reporting crude versus adjusted standardized inci-
dence ratios and/or studies with varying types and degrees
of confounder adjustment. We will use influence analyses
to ascertain whether individual studies were particularly in-
fluential on summary estimates of standardized incidence
ratios. Secondary outcomes will be summarized descrip-
tively and not meta-analyzed, with the exception of stan-
dardized mortality ratios if there are sufficient data.
If at least ten studies are available, we will test for
reporting and other bias using funnel plots with Egger’s
test [34]. However, because funnel plot asymmetry may
not be due to reporting bias, we will attempt to discern
the possible reasons for asymmetry, such as poor meth-
odological quality, differences in the extent of confound-
ing control between smaller and larger studies, and true
heterogeneity in the included studies. All statistical ana-
lyses will be conducted using Comprehensive Meta-Ana-
lysis [35] and STATA version 13 (Stata Corporation,
College Park, TX, USA).Discussion
Our systematic review will provide important informa-
tion regarding the epidemiology of CRC in persons with
HIV relative to non-HIV-infected persons. The results of
this review will be of relevance to clinicians, public
health practitioners, and individuals living with HIV.
Our knowledge dissemination strategies will therefore
include presentations to the community of persons with
HIV, presentations at HIV conferences, and publication
in a peer-reviewed journal. In addition, the results of this
systematic review will be presented to stakeholders par-
ticipating in a future Delphi panel examining whether
existing guidelines for CRC screening are adequate for
persons with HIV.
Additional file
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